Wegovy Could Bankrupt U.S. Health System, Sanders Says In New Report

Blockbuster weight-loss drug Wegovy could bankrupt the U.S. health care system unless the price drops, according to a staff report released Wednesday from the office of Senate Health Committee Chair Bernie Sanders (I-Vt.).

Unless prices dramatically decline, Wegovy and weight loss drugs could push Americans to spend $1 trillion per year on prescription drugs, the report concluded.

“Pricing drugs based on their value cannot serve as a blank check, or the sole determinant for how we understand what to pay for essential goods,” the report stated. As important as these drugs are, they will not do any good for the millions of patients who cannot afford them.”

The report ups the pressure from Sanders on Danish drugmaker Novo Nordisk to lower the price of Wegovy and Ozempic.

In April, Sanders and the Health Committee launched an investigation into why the company is charging Americans substantially higher prices than other countries.

Novo Nordisk charges Americans with Type 2 diabetes $969 per month for Ozempic, compared to just $155 in Canada, $122 in Italy, $71 in France and $59 in Germany.

The company lists Wegovy for $1,349 per month in the U.S. compared to $186 in Denmark, $137 in Germany and $92 in the U.K.

According to the Centers for Disease Control and Prevention, nearly 42 percent of American adults have obesity, and more than 11 percent of the population has diabetes.

If half of American adults with obesity took Wegovy and the other new weight loss drugs, it could cost the health care system $411 billion per year — more than total spending for all retail prescription drugs in 2022, the report found.

The committee report noted the company has not yet provided the net pricing data requested as part of the investigation, but staff estimated net prices to be $809 per month after rebates.

Many private health insurance plans cover the drugs to some extent, though employers and plans have increasingly restricted access or ended coverage completely as they struggle with the costs.

Medicare is prohibited by law from covering drugs solely for weight loss. However, Wegovy was recently approved by the Food and Drug Administration to reduce the risk of serious heart problems in people who are overweight or obese.

With that new approval, the Centers for Medicare and Medicaid Services has opened the door for coverage for more patients.

In a statement, a Novo Nordisk spokesperson said the company is reviewing the report and continues to cooperate with the investigation.

 

Source Link

Recommended Articles

State PBM laws Face ERISA Preemption Challenges in Court

States seeking to limit the power of pharmacy benefit managers are running into legal roadblocks. Every state, as well as the federal government, has enacted PBM legislation over the last decade to rein in an industry accused of anticompetitive business practices. Those efforts have seen mixed results as agencies struggle to enforce requirements and courts ...

Read More

Employer Health Cost Crunch Is Worse Than Projected

There’s new evidence that double-digit health cost increases were hitting employers well before the forecasts of big spikes for 2027 — forcing big changes in workplace coverage for millions of Americans. Why it matters: The findings offer a higher-resolution view of how much health spending is putting a drag on the labor market and increasing ...

Read More

HHS Finalizes Changes To HIPAA Privacy Rule

HHS' Office for Civil Rights finalized a HIPAA privacy rule change cutting the protected health information request response window to 15 calendar days. The final regulation clarifies individuals can retrieve electronic PHI through health apps when entities can support that format.

Read More

Sutter Health-Allina Health Deal Clears Key Hurdle

Sutter Health and Allina Health have achieved a milestone in their plan to merge. The health systems agreed to invest $2.15 billion as part of a 10-year oversight arrangement that Minnesota Attorney General Keith Ellison (D) announced Monday. The deal has been under state review for months. Under terms of the agreement, Sacramento, California-based Sutter ...

Read More
arrowcaret-downclosefacebook-squarehamburgerinstagram-squarelinkedin-squarepauseplaytwitter-squareyoutube-square